MLANA and metastatic melanoma: Similarly, in a phase II study DCs were pulsed with a cocktail of melanoma-associated antigens, including MART-1 or MAGE-A1, MAGE-A2, MAGE-A3, gp100 and tyrosinase, and were subcutaneously injected in metastatic melanoma patients, for which 75% had an antigen-specific CTL response.